Clinical Trial Update: Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations [Phase 2]

View source ↗

Summary

Phase 2 study evaluating neoadjuvant PARP inhibition followed by radical prostatectomy in men with unfavorable intermediate- or high-risk prostate cancer carryi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Unspecified PARP inhibitor

Snippet

Sponsor: Rana McKay, MD | Conditions: Prostate Cancer, BRCA1 Mutation | Phase 2 | Status: RECRUITING